Evidence syntheses
140 structured review questions, each with a registered PICO frame, a reproduced search, an included-studies table, a summary of findings and an amendment log.
A synthesis answers a registered question over a defined evidence base and states how confident the Institute is in each answer. It reproduces its search so that it can be repeated, publishes its extracted data so that it can be checked, and logs every change made after registration so that post-hoc decisions are visible.
Two populations of question. 36 questions were authored individually. 104 were generated by crossing an indication with a compound for which contributing trials exist; their prose frame is templated and every such page says so, while their included studies, summaries of findings and certainty ratings are computed from the underlying records.
Reviews
-
Do incretin-based therapies increase the incidence of acute pancreatitis?
Moderate22 Mar 2026 -
What do published analytical surveys report about the identity, purity and content of peptides obtained from unregulated suppliers?
Low31 Aug 2026 -
What is known about bacterial endotoxin content in peptides supplied for research and injected in practice?
Low05 Feb 2026 -
What proportion of certificates of analysis supplied with research peptides contain the fields required to interpret the reported purity figure?
Moderate20 May 2025 -
How large is the discrepancy between labelled peptide mass and delivered peptide mass when counter-ion and water content are not reported?
High01 Sep 2026 -
How much does a reported chromatographic purity figure vary with the method used to obtain it?
High20 May 2026 -
How is access to incretin-based obesity pharmacotherapy distributed, and what does the pattern of unregulated supply indicate about it?
Low05 Mar 2025 -
In adults with obesity, does a multi-receptor incretin agonist produce a larger reduction in body weight than a single glucagon-like peptide-1 receptor agonist?
Moderate19 Aug 2026 -
What is the incidence of gastrointestinal adverse events and of discontinuation for adverse events with incretin receptor agonists compared with placebo?
High12 Oct 2025 -
What in-use period can be supported for a reconstituted research peptide solution?
Moderate23 Jan 2025 -
Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an efficacy and tolerability profile comparable with an injectable presentation?
Moderate16 Jul 2025 -
To what extent does a change in body weight predict a change in the clinical outcomes for which weight reduction is undertaken?
Low26 Jan 2026 -
What is the effect of reconstitution practice on the dose actually delivered from a lyophilised research peptide?
Moderate05 Nov 2024 -
What is known about the direction and magnitude of the difference between sponsor-conducted and independently conducted trials, and how should an evidence body treat a class whose entire evidence base is sponsor-generated?
Moderate11 Apr 2025 -
What is the evidence that glucagon-like peptide-1 receptor agonism increases the risk of medullary thyroid carcinoma in humans?
Low23 Aug 2024 -
Are the trials in the incretin evidence network sufficiently similar to support indirect comparison?
Moderate11 Mar 2025 -
What proportion of the mass lost during treatment with an incretin receptor agonist is lean rather than fat mass, and does it differ from that lost through caloric restriction?
Low17 Mar 2025 -
In adults who have lost weight during treatment with an incretin receptor agonist, what happens to body weight after treatment is withdrawn?
Moderate09 Mar 2026 -
In adults with type 2 diabetes and chronic kidney disease, what is the effect of a glucagon-like peptide-1 receptor agonist on kidney outcomes?
High07 May 2026 -
In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and weight effect than semaglutide?
High26 Apr 2025
page 1 of 7